PharmAthene Raises $50M To Boost Anti-Bioterror Business

PharmAthene Inc. raised $50 million in its Series B round of financing. The Annapolis, Md.-based company, which is developing products to fight bioterrorism, plans to apply a portion of the funds to continue its development of ToxBlox, an inhibitor of anthrax toxin. (BioWorld Today)